Traitements3programmes
Essais2liés
Publications0liées
SourceDBlocale

Traitements

3
MoléculeIndication / populationPhaseObjectifPaysRésultat
SHR-2173 injectionThis study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of SHR-2173 compared to placebo as an add-on therapy to standard of care (SOC) for the treatment of generalized myasthenia gravis (gMG). The study consists of a 4-week screening period, a 24-week treatment period, and a 12-week safety follow-up period. Lupus, Myasthénie Phase 2 À vérifier China À vérifier
SHR-2173 injectionThis study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of SHR-2173 compared to placebo as an add-on therapy to standard of care (SOC) for the treatment of generalized myasthenia gravis (gMG). The study consists of a 4-week screening period, a 24-week treatment period, and a 12-week safety follow-up period. Myasthénie Phase 2 À vérifier China À vérifier
SHR-2173 injectionThis study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of SHR-2173 compared to placebo as an add-on therapy to standard of care (SOC) for the treatment of generalized myasthenia gravis (gMG). The study consists of a 4-week screening period, a 24-week treatment period, and a 12-week safety follow-up period. Lupus Phase 2 À vérifier China À vérifier

Essais cliniques

2
MoléculeIndication / populationPhaseNCTTitreStatut
SHR-2173 injection Lupus Phase 2 NCT07299422 A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus RECRUITING
SHR-2173 injection Myasthénie Phase 2 NCT07622342 A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis RECRUITING

Publications

0
MoléculeIndication / populationTitreJournalDate
Aucune publication.